[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Helse Stavanger HF\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":385},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,46,76,104,136,182,204,237,258,278,302,333,358],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100543963","phase-2-fasudil-trial-for-treatment-of-early-alzheimers-disease-fead-100543963",false,"NCT06362707","Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)","A Placebo Controlled Randomized Double-blind Parallel Group 12-month Trial of Fasudil for the Treatment of Early Alzheimer's Disease (FEAD)","FEAD","Inclusion Criteria:\n\n* Early AD, eg Stage 3 MCI or Stage 4 (mild AD dementia), as recently defined by the FDA (2018; Figure 2)\n* A significant change on a validated AD amyloid or tau biomarker (as determined either by visual reading of amyloid PET scans using any of the approved ligands, or CSF Aβ 1-42 levels or blood p-tau 217 cut-offs as determined by the clinical research laboratory)\n* A CDR Global rating of 0.5 or 1.0 (Morris 1993) and have an MRI scan within the past two years that has no findings inconsistent with AD\n* Capacity to give informed consent based on the clinical judgement of an experienced clinician\n* The participant needs to have a reliable study partner with regular contact (a combination of face-to-face visits and telephone contact is acceptable) who has sufficient interaction with the participant to provide meaningful input into rating scales\n* Age from 50 years\n* Fluency in Norwegian and evidence of adequate premorbid intellectual functioning\n* Capable of participating in all scheduled evaluations and complete all required tests\n* Female participants must be of non-childbearing potential or have a negative serum pregnancy test within 14 days of baseline assessments and agree to the use of effective birth control throughout their participation in the study\n\nExclusion Criteria:\n\n* Significant cerebrovascular disease, as indicated by clinical history, neurological examination, or on MRI (including cortical infarction or deep white matter or periventricular white matter hyperintensities with a Fazekas scale score of 3 (Fazekas et al 1987).\n* A history of cerebrovascular bleeding or severe bleeding of the digestive tract, lungs, nose or skin\n* Severe renal impairment (GFR \\\u003C30) or serum creatinine or urea nitrogen values ≥3 times Upper normal limit (ULN) at screening or baseline\n* Moderate to severe hepatic impairment. Serum alanine transaminase (ALT) or aspartate transaminase levels ≥3 times ULN at screening or baseline\n* Currently poorly controlled diabetes as indicated by HbA1c values \\>9\n* White blood cell (WBC) values \\\u003C3.5 K\u002Fμl\n* History of paralytic ileus or current severe chronic constipation\n* Known allergy to fasudil or established systemic inflammatory disease or autoimmune disease.\n* Clinically significant hypotension defined by blood pressure values \\\u003C90\u002F60 mmHg, regardless of the individual's sitting or standing position and associated with relevant clinical symptoms (e.g., tachycardia, dizziness, syncope)\n* Current clinically significant depression or other mental disorder likely to affect cognition or interfere with study participation\n* Recent (within 3 months) relevant medication changes. Participants must have been on stable anti-dementia (cholinesterase inhibitors or memantine) or anti-depressive medications for at least three months before the study\n* Participants using sedating drugs, if unavoidable, will be excluded from the study. However, short-acting sleep medications can be used if taken as recommended and if the participant has maintained stability on them for a minimum of 3 months prior to the start of the study\n* Participation in other drug trials\n* Currently ongoing life-threatening disease, such as metastatic cancer, advanced cardiovascular disease, advanced respiratory disease, terminal kidney disease, or advanced stages of infectious diseases\n* Any current or past neurological disease unrelated to Alzheimer's disease with cognitive sequelae\n* A Corrected QT (QTc) interval ≥ 460 milliseconds for males or ≥ 470 milliseconds for females will be considered abnormal during the ECG assessments","ALL","50 Years","100 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The goal of this placebo-controlled double-blind Phase 2 clinical trial is to test in people with early Alzheimer's Disease.\n\nThe main questions it aims to answer are:\n\n* Does treatment with fasudil, a ROCK-inhibitor, lead to significant improvement in working memory (based on computer-based working memory composite scores) compared to placebo in individuals with early Alzheimer's disease (AD) over 12 months?\n* What is the effect of fasudil treatment for 12 months on other cognitive functions, brain metabolism measured by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), and other relevant clinical functions and biomarkers in individuals with early Alzheimer's disease (AD)?\n* Treatment will be escalated to a maintenance dose of 120 mg total daily dose for up to 50 weeks, with regular clinic visits for efficacy and safety evaluations.\n* Assessments will include cognitive tests, FDG-PET scans, and biomarker analyses, with follow-up by the Data and Safety Monitoring Board for ongoing safety review.\n\nThe study will compare participants receiving fasudil with those receiving placebo to see if fasudil treatment leads to improvements in cognitive functions, brain metabolism measured by FDG-PET.",[28,29],"Cognitive Decline, Mild","Alzheimer Disease",[29,31,32],"Mild Cognitive Decline","Fasudil","RECRUITING","2026-04-28",{"date":36,"type":37},"2026-05-04","ACTUAL",{"date":39,"type":37},"2024-08-01",{"date":41,"type":22},"2028-01-01",{"name":43,"class":44},"Helse Stavanger HF","OTHER_GOV",6,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100429148","intramedullary-nail-versus-hip-arthroplasty-in-unstable-trochanteric-hip-fractures-100429148","NCT04868305","Intramedullary Nail Versus Hip Arthroplasty in Unstable Trochanteric Hip Fractures","Randomized Clinical Trial: Treatment of Unstable Trochanteric Hip Fractures With Intramedullary Nail Versus Hip Arthroplasty: Survival, Complications and Postoperative Patient Reported Outcomes","TUFHIPRCT","Inclusion Criteria:\n\n* Age ≥ 65 years\n* American Society of Anesthesiology Score (ASA) \\\u003C 4\n* Ambulant with or without aid (preinjury)\n* Radiological verified unstable trochanteric hip fracture (AO 31A2.2 - 3.3)\n* Written consent obtained by patient or his\u002Fher next of kin\n\nExclusion Criteria:\n\n* Previous hip surgery on ipsilateral or contralateral side\n* Non-ambulant preinjury\n* Patient not living in the area of hospital care","65 Years","120 Years",{"count":57,"type":22},170,[59],"NA","A hip fracture is a large burden to the patient with increased mortality, pain and increased need for daily assistance. Trochanteric fractures of the femur (FTF) represents about 35% of the hip fractures. Today FTFs are mainly treated with internal fixation using sliding hips screws (SHS) or intramedullary nail (IMN), whilst hip arthroplasty (THA\u002FHA) is rarely used. Despite advances in the design of the internal fixation implants there is a high failure rate, in particular in cases of FTFs classified as unstable fractures. Since the introduction of hip arthroplasty in femoral neck fractures there has been a reduction in complication rates, early mobilization and shorter hospital stays.\n\nThe primary objective of this project is to investigate if treatment with hip arthroplasty in unstable FTFs will increase the postoperative mobility, give a better general health outcome for the patient, better quality of life and reduce re-operation rate for the patients compared to those operated with the traditional IMN.",[62,63],"Hip Injuries and Disorders","Hip Fractures",[65,66],"Trochanteric hip fracture","Unstable trochanteric hip fractures","2026-04-25",{"date":69,"type":37},"2026-04-30",{"date":71,"type":37},"2021-10-12",{"date":73,"type":22},"2027-03-31",{"name":43,"class":44},1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":75},"100191056","assessment-of-clinically-related-outcomes-and-biomarker-analysis-for-translational-integration-in-colorectal-cancer-100191056","NCT01762813","Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer","Prospective, Population-based Cohort Collection of Blood Samples and Tumor Tissue From Patients Operated on for Primary or Metastatic Colorectal Cancer","ACROBATICC","Inclusion Criteria:\n\n* Diagnosis of colorectal cancer, primary or metastatic (liver), with a treatment intention of planned curative surgery\n* Informed consent to participate\n* Age ≥18\n\nExclusion Criteria:\n\n* failure to provide written informed consent","18 Years",{"count":86,"type":22},1200,"OBSERVATIONAL","* A prospective, observational study on clinical outcomes of surgical management of primary and metastatic colorectal cancer\n* Prospective collection of tissues to explore potential biomarkers in blood and\u002For primary or secondary cancers and\u002For normal colon",[90],"Colorectal Cancer",[92,93,94,95,96,97],"Colon cancer","rectal cancer","liver metastasis","survival","biomarker","molecular profile",{"date":69,"type":37},{"date":100,"type":37},"2013-01-01",{"date":102,"type":22},"2036-12-31",{"name":43,"class":44},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":111,"maxAge":84,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},"100604114","personalized-digital-treatment-for-adolescent-anxiety-a-feasibility-trial-100604114","NCT07145307","Personalized Digital Treatment for Adolescent Anxiety: A Feasibility Trial","Evaluation of a Personalised Digital Treatment for Adolescents With Anxiety Disorders - A Feasibility Trial in Routine Care","Inclusion Criteria:\n\n* 13 to 18 years old\n* Adequate Norwegian reading, writing and speaking skills\n* Access to the internett and a smart-phone\n* Diagnosed anxiety disorder\n* Receiving outpatient treatment for their anxiety disorder\n* Exposure therapy included in therapy during the study period\n* Therapist agrees to incorporate the app as an ad-on to therapy\n* For patients receiving medication, inclusion requires a stable dose of medication for a psychiatric disorder for six weeks\n\nExclusion Criteria:\n\n* Participants with serious mental illness, such as suicidality or poor general functioning may be excluded if participation is considered unfeasible or potentially harmful. Decision will be based on collaborative evaluation by the participants therapist and the research-team.","13 Years",{"count":113,"type":22},46,[59],"The goal of this feasibility study is to test whether a new blended digital intervention for adolescents with anxiety disorders is feasible and acceptable for use, and to help plan future larger scale studies. The main questions it aims to answer are:\n\n* A: Can the investigators recruit appropriate participants?\n* B: How appropriate are the data collection procedures and outcome measures?\n* C: Are the study procedures and interventions suitable for and acceptable to the participants?\n* D: Does the research team have the resources and ability to manage the study and intervention?\n* E: Does the intervention show promise of being successful for adolescents with anxiety disorders?\n\nParticipants will:\n\n* Receive outpatient anxiety treatment, typically every other week or weekly.\n* Use the Sidekick app as a homework supplement to plan, carry out, and evaluate exposure exercises between treatment sessions.\n* Complete questionnaires before, during, after, and three months after using the app.\n* Some participants and therapists will be invited to take part in qualitative interviews following the intervention.",[117],"Anxiety Disorders",[119,120,121,122,123,124,125,126,127],"anxiety disorders","digital interventions","digital cognitive behavioral therapy","digital ad-on","digital adjunct","adolescents","feasibility trial","exposure therapy","mobile app","2026-04-22",{"date":34,"type":37},{"date":131,"type":37},"2025-10-20",{"date":133,"type":22},"2027-03",{"name":43,"class":44},2,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":143,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":147,"briefSummary":148,"conditions":149,"keywords":161,"overallStatus":173,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":75},"100591636","bridging-affect-consciousness-mentalization-and-trauma--exploring-an-integrative-treatment-approach-for-personality-disorder-pd-100591636","NCT06983002","Bridging Affect Consciousness, Mentalization and Trauma- Exploring an Integrative Treatment Approach for Personality Disorder (PD).","Affect Consciousness (AC) as an Integrated add-on Component in Mentalization-based Group Treatment for Patients With Personality Disorder (PD)- a Mixed Method Explorative Study.","Inclusion Criteria: Participation in a MBT programme for severe AvPD and\u002For BPD 2025-2035. Half the participants join an AC group as add on to standard MBT based on randomisation on a cluster level, 25 % of the rest of the 50% representing the control group patientsample join an Body Awareness Group as add on to proper MBT and the last 25%, representering the control group participates in an Art psychotherapy group as add on to MBT, Norwegian language proficiency, age 20- 40 years.\n\nExclusion Criteria: Diagnosed with schizotypal or antisocial PD, psychotic- or bipolar I disorder, pervasive developmental disorder, ongoing drug\u002F alcohol dependence, organically contingent symptoms and\u002For attention deficit hyperactivity disorder if not effectively treated with medication.","20 Years","40 Years",{"count":146,"type":22},300,[59],"Study background: Specialized Group Outpatient Clinic within specialist mental health services, tailoring two year group treatment programmes for severe Avoidant PD (AvPD) and Borderline PD (BPD) with Affect Consciousness (AC) targeting specific areas of emotional dysfunction. Aims: Our main hypothesis, adding AC to Mentalization- based treatment (MBT) to expand the breadth and depth of therapeutically productive work on affect, will aim to examine health indicators, processes and mechanisms of change in depth. The study will extracts preliminary data after 5 years and 10 years to investigate clinical change, variation and outcome during MBT for PD employing AC as add on to MBT. The study has a randomized controlled trail design, with MBT with or without AC as add-on. The RCT is grounded on original literature on Affect Theory, as a framework for understanding patient functioning, and MBT, framing the therapy.Implications: AC methodology as add on can lead to more tailored treatment programmes, service planning, allocation of resources, guidelines, ACI certification and method development for PDs.",[150,151,152,153,154,155,156,157,158,159,160],"Personality Disorder, Borderline","Personality Trait","Personality Disorder","Personality Type","Personality Disorder, Avoidant","Affect Consciousness","Mentalization","Reflective Functioning","PTSD","PTSD - Post Traumatic Stress Disorder","PTSD and Trauma-related Symptoms",[162,163,155,164,165,166,167,168,169,170,171,172],"Affect Integration","RCT","MBT","AvPD","BPD","Trauma","Personality Disorder (PD)","Personality functioning","Emotional dysfunction","Bodily Awareness","Art Therapy","NOT_YET_RECRUITING","2025-05-13",{"date":176,"type":37},"2025-05-21",{"date":178,"type":22},"2025-05-19",{"date":180,"type":22},"2035-04-19",{"name":43,"class":44},{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":190,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":75},"100174962","stavanger-university-hospital-inflammatory-bowel-disease-trial-100174962","NCT01551563","Stavanger University Hospital Inflammatory Bowel Disease Trial","Management of Inflammatory Bowel Disease in the Stavanger Area - a Prospective Evaluation of Standardized Treatment Regimens on Disease Outcome With Focus on Mucosal Healing and Associations to Fatigue","SUSI","Inclusion Criteria:\n\n* newly diagnosed IBD\n\nExclusion Criteria:\n\n* previous IBD with specific treatment within 10 year\n* inability to consent\n* inability to adhere to treatment protocol","16 Years","80 Years",{"count":193,"type":22},700,"The study aims at studying the outcomes of a protocol-based handling of newly diagnosed Inflammatory bowel disease ( IBD ) patients within a defined uptake area in Norway. It is a descriptive study and no hypothesis is predefined.\n\nCytokine studies, QoL and fatigue assessment will be included for hypothesis-generating purposes.",[196],"IBD",{"date":198,"type":37},"2025-05-16",{"date":200,"type":4},"2012-04",{"date":202,"type":22},"2030-12",{"name":43,"class":44},{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":212,"sex":17,"minAge":213,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":23,"phases":217,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":236},"100517682","phase-4-antibiotics-microbiology-and-immunology-in-children-with-chronic-wet-cough---the-amic-study-100517682","NCT06020716","Antibiotics, Microbiology and Immunology in Children With Chronic Wet Cough - the AMIC Study","A Phase 4 Double Blinded Study With Two Different Interventions, Each With Two Arms, to Evaluate the Clinical Efficacy of Antibiotics and the Role of Microbiology, Immunology and Genetics in Children Aged 9-36 Months With Chronic Wet Cough.","AMIC","Inclusion Criteria:\n\n1. Age ≥ 9 and \\\u003C 36 months.\n2. Body weight ≥ 7 kg and \\\u003C 24 kg.\n3. Born term with Gestational age ≥ 37 weeks.\n4. Chronic wet cough for \\> 4 weeks at screening and in addition average cough score last 7 days at randomization ≥ 4 points and without signs of another cause. Registration ≥ 5 days is mandatory.\n5. Written informed consent obtained from both parents at inclusion.\n6. The study subject must be assessed as eligible for treatment with Augmentin.\n\nExclusion Criteria:\n\n1. Gestational age \\\u003C 37 weeks.\n2. History of acute upper or lower airway infection the last 2 weeks.\n3. History of other viral or bacterial infections the last 2 weeks.\n4. Episode with temperature above 38 °C during the last 2 weeks.\n5. Previous diagnosed with chronic lung disease such as cystic fibrosis, primary ciliary dyskinesia, interstitial lung disease, asthma, immunodeficiency, esophagus atresia.\n6. Cardiac disease, except persisting foramen ovale or ductus arteriosus.\n7. Severe feeding problems\u002Faspiration.\n8. Gastroesophageal reflux suspicion or confirmed by ph measurement.\n9. Suspicion of hypertrophic tonsils or adenoids\n10. Episodes of bronchopulmonary obstruction suggesting asthma\n11. Presence of gross neurodevelopmental delay, or suspicion of neurological disease.\n12. History of known or suspected allergic reactions to amoxicillin-clavulanate or any other betalactam.\n13. Episodes with haemoptysis and with unknown cause.\n14. Radiographic changes other than perihilar changes confirmed by x-ray at screening.\n15. At examination: Digital clubbing, hypoxia, chest wall deformity, dyspnoea at rest.\n16. Parents unable to speak and\u002For understand Norwegian language.\n17. Received systemic antibiotics within the last 6 months before inclusion.\n18. Participation in another clinical intervention trial.",true,"9 Months","36 Months",{"count":216,"type":22},350,[218],"PHASE4","The AMIC study is a double-blind, placebo-controlled, multicenter, nationwide, randomized controlled academic pharmaceutical trial.\n\nOVERALL PRIMARY OBJECTIVES:\n\n* To study the clinical efficacy of antibiotics in children with chronic wet cough (CWC).\n* To study if duration of treatment with antibiotics in children with CWC has impact on efficacy or time to relapse of symptoms.\n\nOVERALL SECONDARY OBJECTIVE:\n\n-To study respiratory pathogens and the diversity\u002Fcomposition of airway and gut microbiome in children with CWC compared to healthy controls, and changes in pathogens\u002Fmicrobiome after treatment with antibiotics.\n\nOVERALL TERTIARY OBJECTIVE:\n\n-To study the role of inflammation, immunology, and genetics in children with chronic wet cough and suspicion of PBB to increase the knowledge of pathophysiological mechanisms associated with PBB.\n\nThe study will include two different RCTs AMIC 1 and AMIC 2:\n\nAMIC 1:\n\nParticipants will be randomly assigned to 14 days amoxicillin-clavulanate syrup or placebo.\n\nAMIC 2:\n\nParticipants will be randomly assigned 1:1 to receive either 14 or 28 days with amoxicillin-clavulanate syrup.",[221],"Protracted Bacterial Bronchitis",[223,224,225,226,227],"Chronic wet cough","Antibiotic","Children","Microbiology","Immunology","2024-12-20",{"date":230,"type":37},"2024-12-27",{"date":232,"type":37},"2023-08-16",{"date":234,"type":22},"2028-04-30",{"name":43,"class":44},7,{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":23,"phases":246,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":236},"100532369","small-macular-holes-treated-with-air-100532369","NCT06211907","Small Macular Holes Treated With Air","Small Macular Holes Treated With Air: A Prospective Randomized Controlled Multicenter Trial","Inclusion Criteria:\n\n* Primary MH ≤250 μm\n* MH duration ≤12 months\n* No previous vitreoretinal surgery in study eye\n* Ability to sign informed consent\n* Signed informed consent\n* Age ˃18 years\n\nExclusion Criteria:\n\n* Previous vitreoretinal surgery in study eye\n* Secondary MH caused by other conditions than vitreomacular traction\n* Myopic MH, i.e., excessive myopia (more than -6 dioptres)\n* Traumatic MH\n* MH secondary to retinal detachment or other retinal diseases\n* Previously participation in this study",{"count":245,"type":22},132,[59],"Non-inferiority trial comparing intraocular air and gas tamponade for closure of macular holes.",[249],"Macular Holes","2024-11-04",{"date":252,"type":37},"2024-11-06",{"date":254,"type":37},"2024-07-14",{"date":256,"type":22},"2028-06-30",{"name":43,"class":44},{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":264,"enrollmentInfo":265,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":75},"100484586","choroidal-blood-flow-in-acute-and-chronic-central-serous-chorioretinopathy-100484586","NCT05589974","Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy","Inclusion Criteria:-\n\n* Able to sign informed consent\n* Possible to obtain fundus imaging\n* Acute CSC ˂4 months of duration in one eye, defined as:\n\n  1. Subfoveal presence of SRF on OCT\n  2. Present attack is 1st -3rd attack of CSC\n\n  b) Patient history and examination consistent with acute CSC c) Characteristic appearance of acute CSC on fundus autofluorescence (FAF) and OCT\n* Chronic CSC ≥4 months of duration in one eye, defined as:\n\n  1. Subfoveal presence of SRF on OCT\n  2. Subjective visual loss\u002Fsymptoms\n  3. Characteristic appearance of chronic CSC on FAF, fluorescein angiography (FA), and indocyanin angiography (ICGA) and OCT\n  4. Patient history and examination consistent with chronic CSC\n\nExclusion Criteria:\n\n* History of retinal disease other than CSC (e.g. retinal detachment)\n* Contraindications for FA, ICGA or PDT (only for chronic CSC)","70 Years",{"count":266,"type":22},50,"Patients with central serous chorioretinopathy (CSC) will be monitored with laser speckle flow graphy (LSFG), swept source optical coherence tomography (SS-OCT) and SS-OCT angiography (SS-OCTA). The aim is to unveil the flow and pulse wave characteristics of the choroidal circulation in acute CSC and chronic CSC.",[269],"Central Serous Chorioretinopathy","2024-03-14",{"date":272,"type":37},"2024-03-18",{"date":274,"type":37},"2022-10-01",{"date":276,"type":22},"2026-07-31",{"name":43,"class":44},{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":17,"minAge":285,"maxAge":4,"enrollmentInfo":286,"targetDuration":288,"studyType":87,"phases":4,"briefSummary":289,"conditions":290,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":301,"locationsCount":75},"100375166","patient-trajectories-for-older-adults-admitted-to-hospital-for-alcohol-related-problems-100375166","NCT04164940","Patient Trajectories for Older Adults Admitted to Hospital for Alcohol-related Problems","A Multi-centre Registry Study on Patient Trajectories After Interventions for Alcohol-related Health Problems in Somatic Hospital Wards, for People in Late Adulthood (60+)","Inclusion Criteria:\n\n* Age 21 or older, no previous alcohol use disorder or substance use disorder, admitted to hospital which has implemented screening and brief alcohol intervention strategies, written consent to participate\n\nExclusion Criteria:\n\n* specialized treatment for alcohol use disorder og drug use disorder during the three years prior to recruitment","21 Years",{"count":287,"type":22},500,"3 Years","Alcohol is contributing to many health problems and disorders, as well as accidents and social problems. Alcohol consumption has been on the rise the past 25 years, especially in Norway. The highest increase is found in older adults, in line with the development in most other countries in the western world. Older adults have a higher risk for alcohol related health problems, due to age related physiological changes, medical conditions and medications. Still, alcohol use is seldom addressed for older people. This means that older people rarely receive help to change alcohol habits.\n\nNorwegian health authorities have issued mandates ordering the regional health trusts to implement strategies in somatic hospital wards, mental health services and drug treatment services to identify and treat alcohol and drug problems affecting the patients' health.\n\nIn this observational study we will explore patient trajectories three years prior to and three years after an admittance to hospital where risky or harmful alcohol consumption is identified and brief interventions are delivered. Hospitals that have implemented such strategies are invited to the study. Patient trajectories are studied in national health registries. This will provide important knowledge on what characterizes the patients identified, and what happens after they have received a brief intervention related to a hospital admittance.",[291,292,293,294],"Alcohol Consumption","Alcohol; Harmful Use","Health Risk Behaviors","Alcohol Dependence","2023-11-21",{"date":297,"type":37},"2023-11-24",{"date":299,"type":37},"2019-10-23",{"date":202,"type":22},{"name":43,"class":44},{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":309,"targetDuration":311,"studyType":87,"phases":4,"briefSummary":312,"conditions":313,"keywords":321,"overallStatus":173,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":4},"100524935","norwegian-adult-mental-health-registry-100524935","NCT06115200","Norwegian Adult Mental Health Registry","NAMHR","Inclusion Criteria:\n\n* Residents in Norway aged 18 years or older assessed and granted right to treatment in specialized mental in- and out-patient settings\n\nExclusion Criteria:\n\n* Persons who have reserved themselves against participation\n* Persons already included in more specialized register for mental disorder and\u002For treatment",{"count":310,"type":22},150000,"6 Months","\"The Norwegian Adult Mental Health Registry\" (NAMHR) is a medical quality register collecting and systematizing data on patients and their treatment in specialist mental health care for adults in Norway. The main purpose is to create a documentation basis for quality assurance, evaluation, and improvement of assessment and treatment for patients who are offered treatment for mental disorders in the specialist health service. The register uses automatic data capture from various existing data sources. New patients are automatically included, but given the opportunity for reservations from the register without affecting their services and treatment.",[314,315,316,317,117,318,319,320],"Depression","Schizophrenia","Bipolar Disorder","Eating Disorders","Ptsd","Personality Disorders","Adhd",[322,323,324],"database","epidemiology","mental health register","2023-11-01",{"date":327,"type":37},"2023-11-02",{"date":329,"type":22},"2024-01-01",{"date":331,"type":22},"2030-12-31",{"name":43,"class":44},{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":11,"sex":17,"minAge":144,"maxAge":19,"enrollmentInfo":340,"targetDuration":4,"studyType":23,"phases":341,"briefSummary":342,"conditions":343,"keywords":345,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":75},"100453690","blood-based-biomarkers-for-diagnosis-of-alzheimers-100453690","NCT05187819","Blood-based Biomarkers for Diagnosis of Alzheimer's","Accuracy of Blood-based Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice","Inclusion Criteria:\n\n* Participants suspected by their GP to have possible dementia, based on history, clinical examination and\u002For cognitive screening\n\nExclusion Criteria:\n\n* Lack of capacity for consent as judged by the GP.\n* Severe psychiatric disease, use of medication or physical disease that according to the GP may affect participation or likely contribute significantly to the observed cognitive impairment.\n* Patients not wanting to be referred to the memory outpatient clinic.",{"count":146,"type":22},[59],"Alzheimer's disease (AD) may currently be diagnosed using molecular biomarkers in cerebrospinal fluid (CSF) and\u002For positron emission tomography (PET). These diagnostic procedures are highly accurate, but the high cost and low availability hamper their feasibility. Recently, ultrasensitive blood tests predicting Alzheimer pathologies in the brain have been developed. These tests have a reliable ability to differentiate AD from other neurodegenerative disorders and identify AD across the clinical continuum with high sensitivity and specificity in research cohorts with a high prevalence of AD.\n\nThis project will assess the predictive value of these tests in a general practice population.\n\nThe hypothesis is that the actual blood panel will have high positive predictive value for a diagnosis of Alzheimer's disease in the primary health care setting.",[344],"Dementia Alzheimers",[346,347,348,349],"Alzheimer's dementia","Diagnosis","Biomarkers","Clinical practice","2023-09-26",{"date":352,"type":37},"2023-09-28",{"date":354,"type":37},"2023-06-01",{"date":356,"type":22},"2029-12-31",{"name":43,"class":44},{"id":359,"slug":360,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":212,"sex":366,"minAge":367,"maxAge":191,"enrollmentInfo":368,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":370,"conditions":371,"keywords":374,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":75},"100484418","monitoring-of-chronic-conditions-in-breast-cancer-100484418","NCT05587777","Monitoring of Chronic Conditions in Breast Cancer","REsearch on BrEast Cancer Induced Chronic Conditions Supported by Causal Analysis of Multi-source Data","REBECCA-1","Inclusion Criteria:\n\n* Breast cancer patients with histologically detectable M0 breast cancer (stage 0-III) who require neoadjuvant or adjuvant endocrine, chemo and \u002F or radiation therapy at least and no more than 3 months before initiation of study.\n* Female breast cancer patients between 19 and 80 years of age.\n* Patients who have increased their life expectancy beyond the first 3 months after starting treatment.\n* Patients who have the ability to understand the protocol and can participate in the follow-up plan.\n* Patients who have an absence of psychological, familial, sociological or geographical condition that potentially impedes compliance with the study protocol and follow-up plan.\n\nExclusion criteria:\n\n* Male breast cancer patients.\n* Patients who do not agree to the study protocol.\n* Patients with a previous cancer diagnosis (excluding skin cancer treated only by surgery).\n* Patients who have previously been treated with some form of chemotherapy \u002F radiation therapy.","FEMALE","19 Years",{"count":369,"type":22},150,"REBECCA-1 is an observational study. Clinical research is undergoing a revolutionary change. The use of electronic patient records (EHR), digital registers, smartphones etc will create \"real-world data\" (RWD) that provides great opportunities for advancing clinical research, but so far this opportunity has been little exploited. The REBECCA -1 study will observe and monitor fatigue in breast cancer survivors. Investigators will use self reported questionnaires (PROM-data), blood tests and objective regulations like the REBECCCA -1 smart watch that will register amount of steps every day, leaving the house, visiting friends, cafes etc. There will be three observational arms; 1.high fatigue, 2. low fatigue and 3. a healthy control arm. After the patients have finished their treatment, they will receive the REBECCA smart watch, a REBECCA app on the smart phone and a REBECCA plus device on their computer, The next offend are also invited to report their evaluation through the same apps. The observational time will be 1 year and comparison between the subjective PROM data , the objective REBECCA watch and the biological samples will be obtained.",[372,373],"Breast Cancer","Chronic Fatigue Syndrome",[375,376],"fatigue","breast cancer","2022-10-19",{"date":379,"type":37},"2022-10-20",{"date":381,"type":37},"2022-06-15",{"date":383,"type":22},"2028-06-15",{"name":43,"class":44},""]